Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease — T.-Christian H. Mix (2005) | RDL Network
Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao-Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai‐Uwe Eckardt, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans‐Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Hajime Uno
Finnian R. Mc Causland, Brian Claggett, Emmanuel A. Burdmann, Kai‐Uwe Eckardt, Reshma Kewalramani, Andrew S. Levey, John J.V. McMurray, Patrick S. Parfrey, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Marc A. Pfeffer
Hicham Skali, Julie Lin, Marc A. Pfeffer, Chao-Yin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Jérôme Rossert, Patrick S. Parfrey, Nairne Scott‐Douglas, Ajay Singh, Robert D. Toto, Hajime Uno, Peter Ivanovich
Finnian R. Mc Causland, Brian Claggett, Emmanuel A. Burdmann, Glenn M. Chertow, Mark E. Cooper, Kai‐Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans‐Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Marc A. Pfeffer
Hicham Skali, Julie Lin, Marc A. Pfeffer, Chaoyin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Patrick S. Parfrey, Nairne Scott‐Douglas, Ajay Singh
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.